Trial Profile
A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Oct 2023
Price :
$35
*
At a glance
- Drugs Artesunate (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Imatinib (Primary) ; Infliximab (Primary) ; Metablok-Arch Biopartners (Primary) ; Lopinavir/ritonavir
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms CATCO
- 12 Oct 2023 Planned primary completion date changed from 18 Mar 2023 to 10 Mar 2024.
- 12 Oct 2023 Status changed from recruiting to active, no longer recruiting.
- 26 Apr 2022 Treatments section has been updated to replace Losartan with Angiotensin II receptor blockers. The type of ARB received will be dependent on what is available at the hospitals.